MedTrace Logo

Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases

NCT03606499 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of ustekinumab on extra-intestinal manifestations (EIMs) and immune-mediated inflammatory diseases (IMIDs) associated with inflammatory bowel disease (IBD) (both Crohn's Disease \[CD\] and Ulcerative Colitis \[UC\]).

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Interventions

DRUG

Ustekinumab

No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.

Sponsors & Collaborators

  • Janssen Cilag S.A.S.

    lead INDUSTRY

Principal Investigators

  • Janssen Cilag S.A.S., France Clinical Trial · Janssen Cilag S.A.S.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-26
Primary Completion
2023-03-17
Completion
2023-03-17

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03606499 on ClinicalTrials.gov